Non-contraceptive benefits of oral contraceptives;Nicht-kontrazeptiver nutzen der pille - Ein oft unbeachteter fakt

Zentralblatt fur Gynakologie

Volumn 122, Issue 1, 2000, Pages 18-27

  Garbe, E ^a   Heinemann, L A J ^a,b,e   Rabe, T ^c   Winkler, U H ^d  

^a Institut fur Pharmakoepidemiologie   (Germany)

^b Berliner Hochschulmedizin   (Germany)

^c UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^d Friedrich Ebert Krankenhaus   (Germany)

^e ZKG Zentrum Epidemiol u G   (Germany)

Author keywords

Endometrial cancer; Iron deficiency anaemia; Oral contraceptives; Ovarian cancer; Rheumatoid arthritis; Salpingitis

Indexed keywords

ORAL CONTRACEPTIVE AGENT;

DRUG EFFECT; FEMALE; HUMAN; IRON DEFICIENCY; MAJOR CLINICAL STUDY; ORAL CONTRACEPTION; OVARY CANCER; REVIEW; RHEUMATOID ARTHRITIS; SALPINGITIS; UTERINE CERVIX CANCER;

ARTHRITIS, RHEUMATOID; BREAST DISEASES; BREAST NEOPLASMS; COHORT STUDIES; CONTRACEPTIVES, ORAL; FEMALE; GENITAL NEOPLASMS, FEMALE; GERMANY; HUMANS; ODDS RATIO; PELVIC INFLAMMATORY DISEASE; PREGNANCY; RISK ASSESSMENT; WOMEN'S HEALTH;

EID: 0033967178     PISSN: 00444197     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (104)

1. Oral contraceptive use and the risk of endometrial cancer. The Centers for Disease Control Cancer and Steroid Hormone Study. JAMA 249 (1983) 1600-1604
2. PID associated with fertility regulating agents. Task Force on Intrauterine Devices, Special Programme of Research, Development and Research Training in Human Reproduction, World Health Organization. Contraception 30 (1984) 1-21
3. The reduction in risk of ovarian cancer associated with oral-contraceptive use. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. N Engl J Med 316 (1987) 650-655
4. Combination oral contraceptive use and the risk of endometrial cancer. The Cancer and Steroid Hormone Study of the Centers for Disease Control and the National Institute of Child Health and Human Development. JAMA 257 (1987) 796-800
5. Endometrial cancer and combined oral contraceptives. The Who Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 17 (1988) 263-269
6. Epithelial ovarian cancer and combined oral contraceptives. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Epidemiol 18 (1989) 538-545
7. Depot-medroxyprogesterone acetate (DMPA) and risk of endometrial cancer. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Int J Cancer 49 (1991) 186-190
8. Allebeck P, Ahlbom A, Ljungstrom K and Allander E: Do oral contraceptives reduce the incidence of rheumatoid arthritis? A pilot study using the Stockholm County medical information system. Scand J Rheumatol 13 (1984) 140-146
9. Badawy YA, Bayoumi DM: An epidemiologic study of ovarian cancer. Part 11 : Oral contraceptive use and menstrual events. J Egypt Public Health Assoc 67 (1992) 579-591
10. Beral V, Hannaford P, Kay C: Oral contraceptive use and malignancies of the genital tract. Results from the Royal College of General Practitioners' Oral Contraception Study. Lancet II (1988) 1331-1335
11. Berkowitz GS, Kelsey JL, LiVolsi VA, Holford TR, Merino MJ, Ort S, O'Connor TZ, Goldenberg IS, White C: Oral contraceptive use and fibrocystic breast disease among pre-and postmenopausal women. Am J Epidemiol 120 (1984) 87-96
12. Booth M, Beral V, Maconochie N, Carpenter L, Scott C: A case-control study of benign ovarian tumours. J Epidemiol Community Health 46 (1992) 528-531
13. Booth M, Beral V, Smith P: Risk factors for ovarian cancer: a case-control study. Br J Cancer 60 (1989) 592-598
14. Brennan P, Bankhead C, Silman A, Symmons D: Oral contraceptives and rheumatoid arthritis: results from a primary care-based incident case-control study. Semin Arthritis Rheum 26 (1997) 817-823
15. Brinton LA, Vessey MP, Flavel R, Yeates D: Risk factors for benign breast disease. Am J Epidemiol 113 (1981) 203-214
16. Casagrande JT, Pike MC, Ross RK, Louie EW, Roy S, Henderson BE: "Incessant ovulation" and ovarian cancer. Lancet II (1979) 170-173
17. Chan WY, Dawood MY: Prostaglandin levels in menstrual fluid of nondysmenorrheic and of dysmenorrheic subjects with and without oral contraceptive of ibuprofen therapy. Adv Prostaglandin Thromboxane Res 8 (1980) 1443-1447
18. Collaborative Group on Hormonal Factors in Breast Cancer: Breast cancer and hormonal contraceptives. Lancet 347 (1996) 1713-1727
19. del Junco DJ, Annegers JF, Luthra HS, Coulam CB, Kurland LT: Do oral contraceptives prevent rheumatoid arthritis? JAMA 254 (1985) 1938-1941
20. Edelman, DA: Pelvic inflammatory disease and contraceptive practice. Adv Contracept 2 (1986) 141-144
21. Eschenbach DA, et al.: Pathogenesis of acute pelvic inflammatory disease: role of contraception and other risk factors. Am J Obstet Gynecol 128 (1977) 838-850
22. Fasal E, Pfaffenbarger RS: Oral contraceptives as related to cancer and benign lesions of the breast. J Natl Cancer Inst 55 (1975) 767-773
23. Faulkner WL, et al.: Intrauterine devices and acute pelvic inflammatory disease. JAMA 235 (1976) 1851-1853
24. Franceschi S, La Vecchia C, Parazzini F, Fasoli M, Regallo M, Decarli A, Gallus G, Tognoni G: Oral contraceptives and benign breast disease: a case-control study. Am J Obstet Gynecol 149 (1984) 602-606
25. Gross TP, Schlesselman JJ, Stadel BV, Yu W, Lee NC: The risk of epithelial ovarian cancer in short-term users of oral contraceptives. Am J Epidemiol 136 (1992) 46-53
26. Hankinson SE,Colditz GA, Hunter DJ, Willett WC, Stampfer MJ, Rosner B, Hennekens CH, Speizer FE: A prospective study of reproductive factors and risk of epithelial ovarian cancer. Cancer 76 (1995) 284-290
27. Hannaford PC, Kay CR: Oral contraceptives and rheumatoid arthritis: new data from the Royal College of General Practitioners' Oral Contraception Study. Br J Rheumatol 28 (1989) Suppl. 1, 36
28. Hartge P, Schiffman MH, Hoover R, McGowan L, Lesher L, Norris HJ: A case-control study of epithelial ovarian cancer. Am J Obstet Gynecol. 161 (1989) 10-16
29. Hazes JM, Silman AJ, Brand R, Spector TD, Walker DJ. Vandenbroucke JP: A case-control study of oral contraceptive use in women with rheumatoid arthritis and their unaffected sisters. Br J Rheumatol 28 (1989) Suppl. 1, 35
30. Heinemann LAJ, Garbe E: Cardiovascular Risks Associated with Oral Contraceplives. In: Fertility Control - Update and Trends. Eds.: Rabe T, Runnebaum B. Berlin: Springer 1999, 91-119
31. Henderson BE, Casagrande JT, Pike MC, Mack T, Rosario I, Duke A: The epidemiology of endometrial cancer in young women. Br J Cancer 47 (1983) 749-756
32. Hernandez Avila M, Liang MH, Willett WC, Stampfer MJ, Colditz GA, Rosner B, Chang RW, Hennekens CH, Speizer FE: Oral contraceptives, replacement oestrogens and the risk of rheumatoid arthritis. Br J Rheumatol 28 (1989) Suppl. 1, 31
33. Hislop TG, Threlfall WJ: Oral contraceptives and benign breast disease. Am J Epidemiol 120 (1984) 273-280
34. Holt VL, Daling JR, McKnight B, Moore D, Stergachis A, Weiss NS: Functional ovarian cysts in relation to the use of monophasic and triphasic oral contraceptives. Obstet Gynecol 79 (1992) 529-533
35. Hoskins WJ: Prospective on ovarian cancer: why prevent? J Cell Biochem 23 (1995) Suppl., 189-199
36. Hsieh CC, Crosson AW, Walker AM, Trapido EJ, MacMahon B: Oral contraceptive use and fibrocystic breast disease of different histologic classifications. J Natl Cancer Inst 72 (1984) 285-290
37. Jorgensen C, Picot MC, Bologna C, Sany J: Oral contraception, parity, breast feeding, and severity of rheumatoid arthritis. Ann Rheum Dis 55 (1996) 94-98
38. Kaufman DW, et al: Intrauterine contraceptive device use and pelvic inflammatory disease. Am J Obstet Gynecol 136 (1980) 159-162
39. Kaufman DW, Shapiro S, Slone D, Rosenberg L, Miettinen OS, Stolley PD, Knapp RC, Leavitt T Jr, Watring WG, Rosenshein NB, Lewis JL, Schottenfeld D, Engle RL Jr: Decreased risk of endometrial cancer among oral-contraceptive users. N Engl J Med 303 (1980) 1045-1047
40. Kay CR, Wingrave SJ: Oral contraceptives and rheumatoid arthritis [letter]. Lancet I (1983) 1437
41. Kelsey JL, et al.: Oral contraceptives and breast disease: an epidemiological study. Am J Epidemiol 107 (1978) 236-244
42. Koepsell T, Dugowson C, Voigt L, Bley L, Nelson JL, Daling J, Setterholm D, Stephens C, Ure C, Ballard J, et al.: Preliminary findings from a case-control study of the risk of rheumatoid arthritis in relation to oral contraceptive use. Br J Rheumatol 28 (1989) Suppl. 1, 41
43. Koumantaki Y, Tzonou A, Koumantakis E, Kaklamani E, Aravantinos D, Trichopoulos D: A case-control study of cancer of endometrium in Athens. Int J Cancer 43 (1989) 795-799
44. La Vecchia C, Decarli A, di Pietro S, Franceschi S, Negri E, Parazzini F: Menstrual cycle patterns and the risk of breast disease. Eur J Cancer Clin Oncol 21 (1985) 417-422
45. La Vecchia C, Decarli A, Fasoli M, Franceschi S, Gentile A, Negri E, Parazzini F, Tognoni G: Oral contraceptives and cancers of the breast and of the female genital tract. Interim results from a case-control study. Br J Cancer 54 (1986) 311-317
46. Lanes SF, Birmann B, Walker AM, Singer S: Oral contraceptive type and functional ovarian cysts. Am J Obstet Gyne-col 166 (1992) 956-961
47. Lees AW, et al.: Oral contraceptives and breast disease in premenopausal Northern Albertan women. Int J Cancer 22 (1978) 700-707
48. Levi F, La Vecchia C, Gulie C, Negri E, Monnier V, Franceschi S, Delaloye JF, De Grandi P: Oral contraceptives and the risk of endometrial cancer. Cancer Causes Control 2 (1991) 99-103
49. Linos A, Worthington JW, O'Fallon WM, Kurland LT: Case-control study of rheumatoid arthritis and prior use of oral contraceptives. Lancet I (1983) 1299-1300
50. Mishell DR Jr. Noncontraceptive benefits of oral contraceptives. J Reprod Med 38 (1993) 1021-1029
51. Newhouse ML, Pearson RM, Fullerton JM, et al: A case control study of carcinoma of the ovary. Br J Prev Soc Med 31 (1977) 148
52. Nilsson L, Rybo G: Treatment of menorrhagia. Am J Obstet Gynecol 110 (1971) 713-720
53. Noonan AS, et al: Gonorrhea screening in an urban hospital Family Planning Program. Am J Public Health 64 (1974) 701-704
54. Odenheimer DJ, Zunzunegui M V, King MC, Shipler CP, Friedman GD: Risk factors for benign breast disease: a case-control study of discordant twins. Am J Epidemiol 120 (1984) 565-571
55. Ory H: Functional ovarian cysts and oral contraceptives. JAMA 228 (1974) 68-69
56. Ory H, Cole P, MacMahon B, Hoover R: Oral contraceptives and reduced risk of benign breast diseases. N Engl J Med 294 (1976) 419-422
57. Osser S, et al.: Risk of pelvic inflammatory disease among users of intrauterine devices, irrespective of previous pregnancy. Am J Obstet Gynecol 138 (1980) 864-867
58. Panser LA, Phipps WR: Type of oral contraceptive in relation to acute, initial episodes of pelvic inflammatory disease. Contraception 43 (1991) 91-99
59. Parazzini F, La Vecchia C, Franceschi S, Decarli A, Gallus G, Regallo M, Liberati A, Tognoni G: Risk factors for pathologically confirmed benign breast disease. Am J Epidemiol 120 (1984) 115-122
60. Parazzini F, La Vecchia C, Franceschi S, Negri E and Cecchetti G: Risk factors for endometrioid, mucinous and serous benign ovarian cysts. Int J Epidemiol 18 (1989) 108-112
61. Parazzini F, La Vecchia C, Negri E, Bocciolone L, Fedele L, Franceschi S: Oral contraceptive use and the risk of ovarian cancer: an Italian case-control study. Eur J Cancer 27 (1991) 594-598
62. Peipert JF, Gutmann J: Oral contraceptive risk assessment: a survey of 247 educated women. Obstet Gynecol 82 (1993) 112-117
63. Pladevall Vila M, Delclos GL, Varas C, Guyer H, Brugues Tarradellas J, Anglada Arisa A: Controversy of oral contra-ceptives and risk of rheumatoid arthritis: meta-analysis of conflicting studies and review of conflicting meta-analyses with special emphasis on analysis of heterogeneity. Am J Epidemiol 144 (1996) 1-14
64. Potischman N, Hoover RN, Brinton LA, Siiteri P, Dorgan JF, Swanson CA, Berman ML, Mortel R, Twiggs LB, Barren RJ, Wilbanks GD, Persky V, Lurain JR: Case-control study of endogenous steroid hormones and endometrial can-cer. J Natl Cancer Inst 88 (1996) 1127-1135
65. Ramcharan S, et al.: The Walnut Creek Contraceptive Study. A prospective study of the side-effects of oral contraceptives. In: National Institutes of Health (Ed.) NIH Publication No. 81-564, Bethesda, 1981
66. Ravnihar B, Seigel DG, Lindtner J: An epidemiologic study of breast cancer and benign breast neoplasias in relation to the oral contraceptive and estrogen use. Eur J Cancer 15 (1979) 395-405
67. Risch HA, Marrett LD, Howe GR: Parity, contraception, infertility, and the risk of epithelial ovarian cancer. Am J Epidemiol 140 (1994) 585-597
68. Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM: Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 117 (1983) 128-139
69. Rohan TE, L'Abbe KA, Cook MG: Oral contraceptives and risk of benign proliferative epithelial disorders of the breast. Int J Cancer 50 (1992) 891-894
70. Romieu I, Hernandez Avila M, Liang MH: Oral contraceptives and the risk of rheumatoid arthritis: a meta-analysis of a conflicting literature. Br J Rheumatol 28 (1989) Suppl. 1, 13-17
71. Rosenberg L, Palmer JR, Zauber AG, Warshauer ME, Lewis JL Jr, Strom BL, Harlap S, Shapiro S: A case-control study of oral contraceptive use and invasive epithelial ovarian cancer. Am J Epidemiol 139 (1994) 654-661
72. Rosenblatt KA, Thomas DB, Noonan EA: High-dose and low-dose combined oral contraceptives: protection against epithelial ovarian cancer and the length of the protective effeet. The WHO Collaborative Study of Neoplasia and Steroid Contraceptives. Eur J Cancer 28 A (1992) 1872-1876
73. Ross RK, Pike MC, Vessey MP, Bull D, Yeates D, Casagrande JT: Risk factors for uterine fibroids: reduced risk associated with oral contraceptives. Br Med J Clin Res Ed 293 (1986) 359-362
74. Royal College of General Practitioners: Oral Contraception and health. An interim report from the oral contraceptive study of the RCGP (1974) (Abstract)
75. Royal College of General Practitioners' Oral Contraception Study. Reduction in incidence of rheumatoid arthritis associated with oral contraceptives. Lancet I (1978) 569-571
76. Ryden G, Fahraeus L, Molin L, Ahman K: Do contraceptives influence the incidence of acute pelvic inflammatory disease in women with gonorrhoea? Contraception 20 (1979) 149-157
77. Sartwell PE, Arthes FG, Tonascia JA: Epidemiology of benign breast lesions: Lack of association with oral contraceptive use. N Engl J Med 288 (1973) 551-554
78. Schlesselman JJ: Oral contraceptives and neoplasia of the uterine corpus. Contraception 43 (1991) 557-579
79. Schlesselman JJ: Net effect of oral contraceptive use on the risk of cancer in women in the United States. Obstet Gynecol 85 (1995) 793-801
80. Shu XO, Brinton LA, Zheng W, Gao YT, Fan J, Fraumeni JF Jr: A population-based case-control study of endometrial cancer in Shanghai, China. Int J Cancer 49 (1991) 38-43
81. Spector TD, Hochberg MC: The protective effect of the oral contraceptive pill on rheumatoid arthritis: an overview of the analytical epidemiological studies using meta-analysis. Br J Rheumatol 28 (1989) Suppl. 1, 11-12
82. Spector TD, Roman E, Silman AJ: A UK case-control study on the effect of parity and the oral contraceptive pill on the development of rheumatoid arthritis. Br J Rheumatol 28 (1989) Suppl. 1, 32
83. Spinillo A, Gorini G, Piazzi G, Baltaro F, Monaco A, Zara F: The impact of oral contraception on chlamydial infection among patients with pelvic inflammatory disease. Contraception 54 (1996) 163-168
84. Stanford JL, Brinton LA, Berman ML, Mortel R, Twiggs LB, Barrett RJ, Wilbanks GD, Hoover RN: Oral contraceptives and endometrial cancer: do other risk factors modify the association? Int J Cancer 54 (1993) 243-248
85. Steinberg WM: Oral contraception: risks and benefits. Adv Contracept 5 (1989) 219-228
86. Svensson L, Westrom Land Mardh PA: Contraceptives and acute salpingitis. JAMA 251 (1984) 2553-2555
87. Targum SD, et al.: Association of the intrauterine device and pelvic inflammatory disease: a retrospective pilot study. Am J Epidemiol 100 (1974) 262-271
88. Tavani A, Negri E, Franceschi S, Parazzini F, La Vecchia C: Risk factors for epithelial ovarian cancer in women under age 45. Eur J Cancer 29A (1993) 1297-1301
89. Tortolero Luna G, Mitchell MF: The epidemiology of ovarian cancer. J Cell Biochem 23 (1995) Suppl., 200-207
90. Trapido EJ: A prospective cohort study of oral contraceptives and cancer of the endometrium. Int J Epidemiol 12 (1983) 297-300
91. Vessey MP, Doll R, Sutton PM: Oral contraceptives and breast neoplasia: A retrospective study. BMJ 3 (1972) 719-724
92. Vessey MP, Painter R: Endometrial and ovarian cancer and oral contraceptives - findings in a large cohort study. Br J Cancer 71 (1995) 1340-1342
93. Vessey MP, Villard Mackintosh L, McPherson K, Yeates D: Mortality among oral contraceptive users: 20 year follow up of women in a cohort study. BMJ 299 (1989) 1487-1491
94. Warner P, Bancroft J: Mood, sexuality, oral contraceptive and menstrual cycle. J Psychosom Res 32 (1988) 417-427
95. Washington AE, Gove S, Schachter J, Sweet RL: Oral contraceptives, Chlamydia trachomatis infection, and pelvic inflammatory disease A word of caution about protection. JAMA 253 (1985) 2246-2250
96. Weiss NS, Sayvetz TA: Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 302 (1980) 551-554
97. Westrom L, et al.: The risk of pelvic inflammatory disease in women using intrauterine contraceptive devices as compared to non-users. Lancet II (1976) 221-224
98. WHO: Oral contraceptives and neoplasia. Report of a WHO Scientific Group. In: WHO Technical Report Series 817. Ed.: World Health Organization. Geneva 1992
99. WHO: Non-contraceptive benefits of oral contraceptives. Progress in Human Reproduction Research No. 39 (1996) (Abstract)
100. Wolner Hanssen P: Oral contraceptive use modifies the manifestations of pelvic inflammatory disease. Br J Obstet Gynaecol 93 (1986) 619-624
101. Wright NH: Unsuspected pelvic infection discovered at tubal ligation: relationship to use of intrauterine contraception. In: Analysis of intrauterine contraception. Eds.: Hefnawi F, Segal SJ. Amsterdam 1976, 401-409
102. Wu ML, Whittemore AS, Paffenbarger RS Jr, Sarles DL, Kampert JB, Grosser S, Jung DL, Ballon S, Hendrickson M, Mohle Boetani J: Personal and environmental characteristics related to epithelial ovarian cancer. I. Reproductive and menstrual events and oral contraceptive use. Am J Epidemiol 128 (1988) 1216-1227
103. Yu H, Rohan TE, Cook MG, Howe GR, Miller AB: Risk factors for fibroadenoma: a case-control study in Australia. Am J Epidemiol 135 (1992) 247-258
104. Zwart S, Meijer LJ: Oral contraceptives are drug of choice for menorrhagia in the Netherlands. BMJ 314 (1997) 75